Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Matrix deal has a big upside

Matrix deal has a big upside

Matrix Pharmaceutical Inc. (MATX) has entered into an agreement with Medeva plc for

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE